Home > Insider Trading > Filing (0001179110-14-016617)

Filing Details

Accession Number:: 0001179110-14-016617
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-11-14 16:03:15
Reporting Period:: 2014-11-12

Filing Date:: 2014-11-14
Accepted Time:: 2014-11-14 16:03:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1280600	Acceleron Pharma Inc	XLRN	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1325710	L Matthew Sherman	128 Sidney Street Cambridge MA 02139	Svp & Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-11-12	2,414	$1.80	22,354	No	4	M	Direct
Common Stock	Acquisiton	2014-11-12	1,504	$5.08	23,858	No	4	M	Direct
Common Stock	Disposition	2014-11-12	1,601	$32.43	22,257	No	4	S	Direct
Common Stock	Disposition	2014-11-12	2,317	$33.59	19,940	No	4	S	Direct
Common Stock	Disposition	2014-11-12	600	$32.64	23,900	No	4	S	Indirect	By GRAT
Common Stock	Disposition	2014-11-12	400	$33.70	23,500	No	4	S	Indirect	By GRAT

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By GRAT
No	4	S	Indirect	By GRAT

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2014-11-12	2,414	$0.00	2,414	$1.80
Common Stock	Option to Purchase Common Stock	Disposition	2014-11-12	1,504	$0.00	1,504	$5.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2017-01-31	No	4	M	Direct
33,496		2018-03-27	No	4	M	Direct

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.97, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $33.98, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.20 to $33.09, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.63 to $33.89, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.